Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
All news
Biotechnology
French company Polyplus-transfection is about to launch a new reagent that has been specifically developed to improve AAV (adeno-associated virus) production in suspension cell culture system for large-scale manufacturing. 6 April 2020
Biotechnology
Following a positive opinion from the European Medicines Agency’s advisory body the CHMP in late February, Japanese pharma giant Takeda today announced that the European Commission has extended the current marketing authorization of Alunbrig (brigatinib). 6 April 2020
Biotechnology
Gilead Sciences has announced a four-year collaboration with Second Genome, to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds. 6 April 2020
Biotechnology
Oxford, UK-based biotech Izana Bioscience today announced the initiation of a two-center compassionate use study involving namilumab (IZN-101) in the treatment of patients with rapidly worsening COVID-19 in cooperation with the Humanitas research group. 6 April 2020
Biotechnology
Samsung Biologics has entered into a strategic partnership with PharmAbcine for the development and manufacturing of oncology and neovascular candidate PMC-402. 6 April 2020
Biotechnology
The US Food and Drug Administration has approved Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent (EMA), for the treatment of anemia failing an erythropoiesis stimulating agent. 6 April 2020
Biotechnology
As the destructive power of COVID-19 skulks through the bourses of every continent, the first quarter of 2020 has delivered a punishing blow for investors in stocks of every stripe. 3 April 2020
Biotechnology
Independent drugmaker Servier has agreed to buy the antibody discovery company Symphogen. 3 April 2020
Biotechnology
Shares in Fate Therapeutics are up more than a tenth after the cellular immunotherapy specialist unveiled a global collaboration and option agreement with Johnson & Johnson. 3 April 2020
Biotechnology
UK-based clinical-stage biotech Axon Neuroscience presented positive results of its Phase II trial for AADvac1, the first tau vaccine to treat and prevent Alzheimer's disease, at the AAT-AD/PD (International Conference on Alzheimer’s & Parkinson’s Diseases) 2020 conference, Vienna, Austria. 3 April 2020
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) held an extraordinary virtual meeting on Thursday. 3 April 2020
Biotechnology
GlaxoSmithKline has presented pivotal data on Nucala that supports a regulatory filing for an additional eosinophil-driven disease. 3 April 2020
Biotechnology
The pivotal Phase III clinical trial results announced today show Dupixent (dupilumab) combined with standard-of-care topical corticosteroids (TCS) in children aged six-11 years with uncontrolled severe atopic dermatitis significantly improved disease signs, symptoms and health-related quality of life. 3 April 2020
Biotechnology
Closely-held US biotech firm Ridgeback Biotherapeutics yesterday announced that it has been awarded a contract for $10.9 million to support the development of ansuvimab (mAb114), an experimental Ebola treatment, through licensure with the US Food and Drug Administration. 3 April 2020
Biotechnology
US biotech giant Amgen and Adaptive Biotechnologies today announced a collaboration aimed at helping address the COVID-19 pandemic. 2 April 2020
Biotechnology
Privately-held drugmaker EUSA Pharma has announced initial preliminary findings from the SISCO study of siltuximab as a treatment for severe COVID-19. 2 April 2020
Biotechnology
Austrian immuno-oncology firm Apeiron Biologics today announced that it has received regulatory approvals in Austria, Germany and Denmark to initiate a Phase II clinical trial of APN01 to treat COVID-19. 2 April 2020
Biotechnology
The US Food and Drug Administration on Wednesday approved Sevenfact (coagulation factor VIIa [recombinant]-jncw) for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies). 2 April 2020
Biotechnology
Gilead Sciences company Kite has entered into a license and collaboration agreement with Teneobio, gaining exclusive rights to certain anti-BCMA antibodies under development. 2 April 2020
Biotechnology
A new strategic partnership aimed at scaling up COVID-19 antigen production has been formed between UK-based Native Antigen Company (NAC) and Oxford Genetics (OXGENE). 2 April 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze